Collapsing focal segmental glomerulosclerosis (cFSGS) and tubuloreticular inclusions (TRIs) are pathological findings that are described more and more in the setting of lupus nephritis. However, these two pathological entities are not a part of the lupus pathological criteria for classification and the clinical presentation and laboratory workup does not always confirm the diagnosis of lupus making the management of these cases sometimes doubtful. We present the case of a 27 year-old woman with cFSGS and TRIs and we try to compare to what the literature provides from case reports to studies relevant to our case in particular.
Petri M, Wallace DJ, Spindler A, Chindalore V, Kalunian K, Mysler E, et al. Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum. 2013;65(4):1011-21.
[3]
Gupta R, Sharma A, Bhowmik D, Gupta S, Agarwal S, Dinda A. Collapsing glomerulopathy occurring in HIV-negative patients with systemic lupus erythematosus: report of three cases and brief review of the literature. Lupus. 2011;20(8):866-70.
[4]
Tungekar MF, Waller S, Clothier JC. Collapsing glomerulopathy in a girl with systemic lupus erythematosus. Pediatr Nephrol. 2011;26(5):809-13.
[5]
Salvatore SP, Barisoni LM, Herzenberg AM, Chander PN, Nickeleit V, Seshan SV. Collapsing glomerulopathy in 19 patients with systemic lupus erythematosus or lupus-like disease. Clin J Am Soc Nephrol. 2012;7(6):914-25.
Lee CJ, Suh KS, Kim KH, Chang YK, Na KR, Lee KW. The clinicopathologic significance of endothelial tubuloreticular inclusions in glomerular diseases. Ultrastruct Pathol. 2013;37(6):386-94.
[8]
Albaqumi M, Barisoni L. Current views on collapsing glomerulopathy. J Am Soc Nephrol. 2008;19(7):1276-81.
[9]
Ross MJ, Klotman PE. Recent progress in HIV-associated nephropathy. J Am Soc Nephrol. 2002;13(12):2997-3004.
[10]
Winston JA, Bruggeman LA, Ross MD, Jacobson J, Ross L, D'Agati VD, et al. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med. 2001;344(26):1979-84.
[11]
D'Agati V. Pathologic classification of focal segmental glomerulosclerosis. Semin Nephrol. 2003;23(2):117-34.
[12]
Mak A, Almsherqi ZA, Lai YW, Cheak AA, Deng Y. Intracellular tubulo-reticular structures of peripheral blood mononuclear cells as an ultra-structural marker of disease activity in systemic lupus erythematosus: a pilot study. Int J Rheum Dis. 2013;16(6):692-7.
[13]
Lech M, Anders HJ. The pathogenesis of lupus nephritis. J Am Soc Nephrol. 2013;24(9):1357-66.
[14]
Urosevic-Maiwald M, Nobbe S, Kerl K, Benz R. Disseminated ulcerating lupus panniculitis emerging under interferon therapy of hairy cell leukemia: treatment or disease-related? Dermatol Online J. 2014;20(3):21727.
[15]
Markowitz GS, Nasr SH, Stokes MB, D'Agati VD. Treatment with IFN-{alpha}, -{beta}, or -{gamma} is associated with collapsing focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2010;5(4):607-15.
[16]
Freedman BI, Kopp JB, Langefeld CD, Genovese G, Friedman DJ, Nelson GW, et al. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J Am Soc Nephrol. 2010;21(9):1422-6.
[17]
Parsa A, Kao WH, Xie D, Astor BC, Li M, Hsu CY, et al. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med. 2013;369(23):2183-96.
[18]
Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-86.
[19]
Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15(2):241-50.
